Insulin-like growth factor (IGF) signaling intumorigenesis and the development ofcancer drug resistance

Genes and Diseases

Volumn 2, Issue 1, 2015, Pages 13-25

  Denduluri, Sahitya K ^a,b   Idowu, Olumuyiwa ^a,b   Wang, Zhongliang ^b,c   Liao, Zhan ^b,d   Yan, Zhengjian ^b,c   Mohammed, Maryam K ^a,b   Ye, Jixing ^b,e   Wei, Qiang ^b,c   Wang, Jing ^b,c   Zhao, Lianggong ^b,f   Luu, Hue H ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b Department of Orthopaedic Surgery and Rehabilitation Medicine   (United States)

^c CHONGQING MEDICAL UNIVERSITY   (China)

^d CENTRAL SOUTH UNIVERSITY   (China)

^e CHONGQING UNIVERSITY   (China)

^f LANZHOU UNIVERSITY   (China)

Author keywords

Cancer; Insulin like growth factor; Resistance; Therapy; Tumorigenesis

Indexed keywords

ANTINEOPLASTIC AGENT; SOMATOMEDIN;

ADJUVANT CHEMORADIOTHERAPY; BONE TUMOR; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM TUMOR; DIGESTIVE SYSTEM CANCER; HEAD AND NECK CANCER; HEALTH CARE QUALITY; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG CANCER; OVARY CANCER; PROSTATE CANCER; REVIEW; SENSITIZATION; SIGNAL TRANSDUCTION; SOFT TISSUE TUMOR;

EID: 84939134492     PISSN: None     EISSN: 23523042     Source Type: Journal    
DOI: 10.1016/j.gendis.2014.10.004     Document Type: Review

References (126)

1. LeRoith D., Roberts C.T. The insulin-like growth factor system and cancer. Cancer Lett 2003, 195:127-137.
2. Vincent A.M., Feldman E.L. Control of cell survival by IGF signaling pathways. Growth Horm IGF Res: official journal of the Growth Hormone Research Society and the International IGF Research Society Aug 2002, 12:193-197.
3. Zha J., Lackner M.R. Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy. Clin Cancer Res: an official journal of the American Association for Cancer Research May 1 2010, 16:2512-2517.
4. Siddle K. Signalling by insulin and IGF receptors: supporting acts and new players. J Mol Endocrinol Aug 2011, 47:R1-R10.
5. Kennedy S.G., Wagner A.J., Conzen S.D., et al. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev Mar 15 1997, 11:701-713.
6. Taniguchi C.M., Emanuelli B., Kahn C.R. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006, 7:85-96. 02//print.
7. Pouyssegur J., Volmat V., Lenormand P. Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. Biochem Pharmacol Sep 2002, 64:755-763.
8. Hwa V., Oh Y., Rosenfeld R.G. The insulin-like growth factor-binding protein (igfbp) superfamily. Endocr Rev 1999, 20:761-787.
9. Sachdev D., Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther Jan 2007, 6:1-12.
10. Pollak M.N., Schernhammer E.S., Hankinson S.E. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004, 4:505-518. 07//print.
11. Hankinson S.E., Willett W.C., Colditz G.A., et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet May 9 1998, 351:1393-1396.
12. Ma J., Pollak M.N., Giovannucci E., et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst April 7, 1999, 91:620-625.
13. Roberts C.T. IGF-1 and prostate cancer. Novartis Found Symp 2004, 262:193-199. discussion 199-204, 265-198.
14. Dziadziuszko R., Camidge D.R., Hirsch F.R. The insulin-like growth factor pathway in lung cancer. J Thorac Oncol: official publication of the International Association for the Study of Lung Cancer Aug 2008, 3:815-818.
15. Livingstone C. IGF2 and cancer. Endocr Relat Cancer. Dec 2013, 20:R321-R339.
16. Su Y., Wagner E.R., Luo Q., et al. Insulin-like growth factor binding protein 5 suppresses tumor growth and metastasis of human osteosarcoma. Oncogene Sep 15 2011, 30:3907-3917.
17. Luther G.A., Lamplot J., Chen X., et al. IGFBP5 domains exert distinct inhibitory effects on the tumorigenicity and metastasis of human osteosarcoma. Cancer Lett Aug 9 2013, 336:222-230.
18. Chen H.X., Sharon E. IGF-1R as an anti-cancer target-trials and tribulations. Chin J Cancer May 2013, 32:242-252.
19. Eccleston A., Dhand R. Signalling in cancer. Nature 2006, 441:423. 05/25/print, 423.
20. Casa A.J., Dearth R.K., Litzenburger B.C., Lee A.V., Cui X. The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Front Biosci: a journal and virtual library 2008, 13:3273-3287.
21. Florea A.-M., Büsselberg D. Breast cancer and possible mechanisms of therapy resistance. J Local Glob Health Sci 2013, 2:1-9.
22. Massarweh S., Osborne C.K., Creighton C.J., et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res Feb 1 2008, 68:826-833.
23. Zhang Y., Moerkens M., Ramaiahgari S., et al. Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes. Breast Cancer Res: BCR 2011, 13:R52.
24. Surmacz E. Function of the IGF-I receptor in breast cancer. J Mammary Gland Biol Neoplasia Jan 2000, 5:95-105.
25. Fox E.M., Kuba M.G., Miller T.W., Davies B.R., Arteaga C.L. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation. Breast Cancer Res: BCR 2013, 15:R55.
26. Winder T., Giamas G., Wilson P.M., et al. Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen. Pharmacogenomics J Feb 2014, 14:28-34.
27. Li C., Harada A., Oh Y. IGFBP-3 sensitizes antiestrogen-resistant breast cancer cells through interaction with GRP78. Cancer Lett Dec 28 2012, 325:200-206.
28. Lu Y., Zi X., Zhao Y., Mascarenhas D., Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001, 93:1852-1857.
29. Ye X.M., Zhu H.Y., Bai W.D., et al. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R. BMC cancer 2014, 14:134.
30. Gallardo A., Lerma E., Escuin D., et al. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. B J Cancer Apr 10 2012, 106:1367-1373.
31. Nahta R. Deciphering the role of insulin-like growth factor-I receptor in trastuzumab resistance. Chemother Res Pract 2012, 2012:648965.
32. Karamouzis M.V., Papavassiliou A.G. Targeting insulin-like growth factor in breast cancer therapeutics. Crit Rev Oncol Hematol Oct 2012, 84:8-17.
33. Liu S., Meng X., Chen H., et al. Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. Oncotarget May 27 2014, 5:9049-9064.
34. Fagan D.H., Uselman R.R., Sachdev D., Yee D. Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment. Cancer Res Jul 1 2012, 72:3372-3380.
35. Engelberth S.A., Hempel N., Bergkvist M. Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics. Crit Rev Oncog 2014, 19:281-315.
36. Walters Haygood C.L., Arend R.C., Straughn J.M., Buchsbaum D.J. Ovarian cancer stem cells: can targeted therapy lead to improved progression-free survival?. World J Stem Cells Sep 26 2014, 6:441-447.
37. Singh R.K., Gaikwad S.M., Jinager A., Chaudhury S., Maheshwari A., Ray P. IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells. Cancer Lett Aug 22 2014, 354:254-262.
38. Koti M., Gooding R.J., Nuin P., et al. Identification of the IGF1/PI3K/NF kappaB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer. BMC Cancer 2013, 13:549.
39. Beltran P.J., Calzone F.J., Mitchell P., et al. Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy. Clin Cancer Res: an official journal of the American Association for Cancer Research Jun 1 2014, 20(11):2947-2958.
40. Brouwer-Visser J., Lee J., McCullagh K., Cossio M.J., Wang Y., Huang G.S. Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer. PloS One 2014, 9:e100165.
41. SEER Stat Fact Sheets: Prostate Cancer. http://seer.cancer.gov/statfacts/html/prost.html.
42. Wu J.D., Haugk K., Woodke L., Nelson P., Coleman I., Plymate S.R. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem 2006, 99:392-401.
43. Scher H.I., Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol: official journal of the American Society of Clinical Oncology Nov 10 2005, 23:8253-8261.
44. Taplin M.E., Balk S.P. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem Feb 15 2004, 91:483-490.
45. Sharma J., Gray K.P., Evan C., et al. Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival. Prostate Feb 2014, 74:225-234.
46. Gray A., Aronson W.J., Barnard R.J., et al. Global Igfbp1 deletion does not affect prostate cancer development in a c-Myc transgenic mouse model. J Endocrinol Dec 2011, 211:297-304.
47. Jones J.I., Gockerman A., Busby W.H., Wright G., Clemmons D.R. Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. Proc Natl Acad Sci U S A Nov 15 1993, 90:10553-10557.
48. Biernacka K.M., Uzoh C.C., Zeng L., et al. Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2. Endocr Relat Cancer Oct 2013, 20:741-751.
49. Seki M., Teishima J., Mochizuki H., et al. Restoration of IGFBP-rP1 increases radiosensitivity and chemosensitivity in hormone-refractory human prostate cancer. Hiroshima J Med Sci Mar 2013, 62:13-19.
50. SEER Stat Fact Sheets: Lung and Bronchus Cancer.
51. Zhang W., Lei P., Dong X., Xu C. The new concepts on overcoming drug resistance in lung cancer. Drug Des Devel Ther 2014, 8:735-744.
52. Peled N., Wynes M.W., Ikeda N., et al. Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. Cell Oncol (Dordr) Jul 2013, 36:277-288.
53. Fidler M.J., Basu S., Buckingham L., et al. Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer. Anticancer Res May 2012, 32:1705-1710.
54. Murakami A., Takahashi F., Nurwidya F., et al. Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor. PloS One 2014, 9:e86459.
55. Suda K., Mizuuchi H., Sato K., Takemoto T., Iwasaki T., Mitsudomi T. The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor. Int J Cancer. Journal international du cancer Aug 15 2014, 135:1002-1006.
56. Vazquez-Martin A., Cufi S., Oliveras-Ferraros C., et al. IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations. Sci Rep 2013, 3:2560.
57. Riely G.J., Pao W., Pham D., et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res: an official journal of the American Association for Cancer Research Feb 1 2006, 12:839-844.
58. Jackman D.M., Yeap B.Y., Sequist L.V., et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res: an official journal of the American Association for Cancer Research Jul 1 2006, 12:3908-3914.
59. Qi H.W., Shen Z., Fan L.H. Combined inhibition of insulin-like growth factor-1 receptor enhances the effects of gefitinib in a human non-small cell lung cancer resistant cell line. Exp Ther Med Nov 2011, 2:1091-1095.
60. Jeannot V., Busser B., Brambilla E., et al. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism. Int J Cancer. Journal international du cancer Jun 1 2014, 134:2560-2571.
61. Kawai M., Breggia A.C., DeMambro V.E., et al. The heparin-binding domain of IGFBP-2 has insulin-like growth factor binding-independent biologic activity in the growing skeleton. J Biol Chem Apr 22 2011, 286:14670-14680.
62. Hantschel O., Rix U., Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma Apr 2008, 49:615-619.
63. Lu H., Wang L., Gao W., et al. IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells. Mol Cancer Ther Dec 2013, 12:2864-2873.
64. Guix M., Faber A.C., Wang S.E., et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest Jul 2008, 118:2609-2619.
65. Choi Y.J., Park G.M., Rho J.K., et al. Role of IGF-binding protein 3 in the resistance of EGFR mutant lung cancer cells to EGFR-tyrosine kinase inhibitors. PloS One 2013, 8:e81393.
66. Zimmermann E.M., Li L., Hoyt E.C., Pucilowska J.B., Lichtman S., Lund P.K. Cell-specific localization of insulin-like growth factor binding protein mRNAs in rat liver. Am J Physiol Gastrointest Liver Physiol Mar 2000, 278:G447-G457.
67. Cortes-Sempere M., de Miguel M.P., Pernia O., et al. IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer. Oncogene Mar 7 2013, 32:1274-1283.
68. Sun Y., Zheng S., Torossian A., et al. Role of insulin-like growth factor-1 signaling pathway in cisplatin-resistant lung cancer cells. Int J Radiat Oncol Biol Phys Mar 1 2012, 82:e563-572.
69. Suzuki H., Igarashi S., Nojima M., et al. IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. Carcinogenesis Mar 2010, 31:342-349.
70. Okamura J., Huang Y., Moon D., Brait M., Chang X., Kim M.S. Downregulation of insulin-like growth factor-binding protein 7 in cisplatin-resistant non-small cell lung cancer. Cancer Biol Ther Feb 1 2012, 13:148-155.
71. Goodenberger M.L., Jenkins R.B. Genetics of adult glioma. Cancer Genet 2012, 205:613-621. 12//.
72. Mirimanoff R.O. High-grade gliomas: reality and hopes. Chin J Cancer Jan 2014, 33:1-3.
73. Osuka S., Sampetrean O., Shimizu T., et al. IGF1 receptor signaling regulates adaptive radioprotection in glioma stem cells. Stem cells (Dayton, Ohio) Apr 2013, 31:627-640.
74. Hsieh A., Ellsworth R., Hsieh D. Hedgehog/GLI1 regulates IGF dependent malignant behaviors in glioma stem cells. J Cell Physiol Apr 2011, 226:1118-1127.
75. Li C., Zhou C., Wang S., et al. Sensitization of glioma cells to tamoxifen-induced apoptosis by Pl3-kinase inhibitor through the GSK-3beta/beta-catenin signaling pathway. PloS One 2011, 6:e27053.
76. Chen M.Y., Clark A.J., Chan D.C., et al. Wilms' tumor 1 silencing decreases the viability and chemoresistance of glioblastoma cells invitro: a potential role for IGF-1R de-repression. J Neurooncol May 2011, 103:87-102.
77. Fuller G.N., Rhee C.H., Hess K.R., et al. Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. Cancer Res Sep 1 1999, 59:4228-4232.
78. Han S., Li Z., Master L.M., Master Z.W., Wu A. Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin beta1-ERK pathway. B J Cancer Aug 5 2014, 111:1400-1409.
79. Takahashi T., Saikawa Y., Kitagawa Y. Gastric cancer: current status of diagnosis and treatment. Cancers 2013, 5:48-63.
80. Bochatay L., Girardin M., Bichard P., Frossard J.L. Pancreatic cancer in 2014: screening and epidemiology. Revue medicale suisse Sep 3 2014, 10:1582-1585.
81. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA: Cancer J Clin Mar-Apr 2011, 61:69-90.
82. Chen K., Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet 2007, 8:93-103. 02//print.
83. Cui Y.H., Xiao L., Rao J.N., et al. miR-503 represses CUG-binding protein 1 translation by recruiting CUGBP1 mRNA to processing bodies. Mol Biol Cell Jan 2012, 23:151-162.
84. Wang T., Ge G., Ding Y., et al. MiR-503 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R and BCL2. Chin Med J 2014, 127:2357-2362.
85. Yang M., Shan X., Zhou X., et al. miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2. Anticancer Agents Med Chem 2014, 14:884-891.
86. SEER Stat Fact Sheets: Colon and Rectum Cancer. http://seer.cancer.gov/statfacts/html/colorect.html.
87. Cohen D.H., LeRoith D. Obesity, type 2 diabetes, and cancer: the insulin and IGF connection. Endocr Relat Cancer Oct 2012, 19:F27-F45.
88. Volkova E., Robinson B.A., Willis J., Currie M.J., Dachs G.U. Marginal effects of glucose, insulin and insulin-like growth factor on chemotherapy response in endothelial and colorectal cancer cells. Oncol Lett Feb 2014, 7:311-320.
89. Lyman G.H., Sparreboom A. Chemotherapy dosing in overweight and obese patients with cancer. Nat Rev Clin Oncol 2013, 10:451-459. 08//print.
90. Haimeur A., Conseil G., Deeley R.G., Cole S.P. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab Feb 2004, 5:21-53.
91. Shen K., Cui D., Sun L., Lu Y., Han M., Liu J. Inhibition of IGF-IR increases chemosensitivity in human colorectal cancer cells through MRP-2 promoter suppression. J Cell Biochem Jun 2012, 113:2086-2097.
92. Hsu H.H., Cheng L.H., Ho T.J., et al. Apicidin-resistant HA22T hepatocellular carcinoma cells massively promote pro-survival capability via IGF-IR/PI3K/Akt signaling pathway activation. Tumour Biol: the journal of the International Society for Oncodevelopmental Biology and Medicine Jan 2014, 35:303-313.
93. Shan J., Shen J., Liu L., et al. Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology (Baltimore, Md.) Sep 2012, 56:1004-1014.
94. Bu Y., Jia Q.A., Ren Z.G., et al. Maintenance of stemness in oxaliplatin-resistant hepatocellular carcinoma is associated with increased autocrine of IGF1. PloS One 2014, 9:e89686.
95. Tian X., Hao K., Qin C., Xie K., Xie X., Yang Y. Insulin-like growth factor 1 receptor promotes the growth and chemoresistance of pancreatic cancer. Dig Dis Sci Sep 2013, 58:2705-2712.
96. Morris J.Pt., Wang S.C., Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer Oct 2010, 10:683-695.
97. Wei F., Liu Y., Bellail A.C., et al. K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas. Cancer Lett Sep 1 2012, 322:58-69.
98. Dropkin M.J. Body image and quality of life after head and neck cancer surgery. Cancer Pract 1999, 7:309-313.
99. So WKW, Chan RJ, Chan DNS, etal. Quality-of-life among head and neck cancer survivors at one year after treatment - a systematic review. Eur J Cancer.48(15):2391-2408.
100. Bier H. Chemotherapeutic drug resistance in the management of head and neck cancer. Eur Arch Otorhinolaryngol: official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS): affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 1993, 250:200-208.
101. Szafarowski T., Szczepanski M.J. Cancer stem cells in head and neck squamous cell carcinoma. Otolaryngologia polska. The Polish Otolaryngology 2014, 68:105-111.
102. Jameson M.J., Beckler A.D., Taniguchi L.E., et al. Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells. Mol Cancer Ther November 1, 2011, 10:2124-2134.
103. Knowlden J., Jones H., Barrow D., Gee J.W., Nicholson R., Hutcheson I. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance. Breast Cancer Res Treat 2008, 111:79-91. /09/01 2008.
104. Chung C.H., Pohlmann P.R., Rothenberg M.L., et al. Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma. Head Neck 2011, 33:1804-1808.
105. Limesand K.H., Chibly A.M., Fribley A. Impact of targeting insulin-like growth factor signaling in head and neck cancers. Growth Horm IGF Res: official journal of the Growth Hormone Research Society and the International IGF Research Society Oct 2013, 23:135-140.
106. Kim S.Y., Toretsky J.A., Scher D., Helman L.J. The role of IGF-1R in pediatric malignancies. Oncologist January 1, 2009, 14:83-91.
107. Wang Y.H., Xiong J., Wang S.F., et al. Lentivirus-mediated shRNA targeting insulin-like growth factor-1 receptor (IGF-1R) enhances chemosensitivity of osteosarcoma cells invitro and invivo. Mol Cell Biochem Aug 2010, 341:225-233.
108. Wang Y.H., Wang Z.X., Qiu Y., et al. Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits growth, reduces invasion, and enhances radiosensitivity in human osteosarcoma cells. Mol Cell Biochem Jul 2009, 327:257-266.
109. Luk F., Yu Y., Walsh W.R., Yang J.L. IGF1R-targeted therapy and its enhancement of doxorubicin chemosensitivity in human osteosarcoma cell lines. Cancer Invest Oct 2011, 29:521-532.
110. Duan Z., Choy E., Harmon D., et al. Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines. Mol Cancer Ther August 1, 2009, 8:2122-2130.
111. Tripathi G., Salih D.A., Drozd A.C., Cosgrove R.A., Cobb L.J., Pell J.M. IGF-independent effects of insulin-like growth factor binding protein-5 (Igfbp5) invivo. FASEB J: official publication of the Federation of American Societies for Experimental Biology Aug 2009, 23:2616-2626.
112. de Souza R.R., Oliveira I.D., del Giudice Paniago M., et al. Investigation of IGF2, Hedgehog and fusion gene expression profiles in pediatric sarcomas. Growth Horm IGF Res: official journal of the Growth Hormone Research Society and the International IGF Research Society Aug 2014, 24:130-136.
113. Kang Z., Yu Y., Zhu Y.J., et al. Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma. Oncogene Dec 2 2013, 1-9.
114. Faye M.D., Beug S.T., Graber T.E., et al. IGF2BP1 controls cell death and drug resistance in rhabdomyosarcomas by regulating translation of cIAP1. Oncogene Apr 7 2014, 1-10.
115. Hirose M., Hosoi E., Hamano S., Jalili A. Multidrug resistance in hematological malignancy. The journal of medical investigation. JMI Aug 2003, 50:126-135.
116. Lichtman M.A. Battling the hematological malignancies: the 200 years' War. Oncologist February 1, 2008, 13:126-138.
117. Barrett D., Brown V.I., Grupp S.A., Teachey D.T. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies. Paediatr Drugs Oct 1 2012, 14:299-316.
118. Bartalucci N., Tozzi L., Bogani C., et al. Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms. J Cell Mol Med Nov 2013, 17:1385-1396.
119. Bauer T.M., Patel M.R., Infante J.R. Targeting PI3 kinase in cancer. Pharmacol Ther Sep 18 2014, 1-8. (in press).
120. Tasian S.K., Teachey D.T., Rheingold S.R. Targeting the PI3K/mTOR pathway in pediatric hematologic malignancies. Front Oncol 2014, 4:108.
121. Kuhn D.J., Berkova Z., Jones R.J., et al. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood Oct 18 2012, 120:3260-3270.
122. Tagoug I., Jordheim L.P., Herveau S., et al. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors. Clin Cancer Res: an official journal of the American Association for Cancer Research Jul 1 2013, 19:3556-3566.
123. Verhagen H.J., de Leeuw D.C., Roemer M.G., et al. IGFBP7 induces apoptosis of acute myeloid leukemia cells and synergizes with chemotherapy in suppression of leukemia cell survival. Cell Death Dis 2014, 5:e1300.
124. Kuhnl A., Kaiser M., Neumann M., et al. High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia. Leuk Res Dec 2011, 35:1585-1590.
125. Laranjeira A.B., de Vasconcellos J.F., Sodek L., et al. IGFBP7 participates in the reciprocal interaction between acute lymphoblastic leukemia and BM stromal cells and in leukemia resistance to asparaginase. Leukemia May 2012, 26:1001-1011.
126. King H., Aleksic T., Haluska P., Macaulay V.M. Can we unlock the potential of IGF-1R inhibition in cancer therapy?. Cancer Treat Rev Oct 2014, 40:1096-1105.